



## Europass Curriculum Vitae



### Personal information

<b>First name/ Surname</b>	<b>Ilary Ruscito</b>
<b>E-mail</b>	ilary.ruscito@uniroma1.it
<b>Nationality</b>	Italian
<b>Position</b>	Medical Doctor, Specialist in Gynecology and Obstetrics. Joint PhD fellow at:  Cell Therapy Unit and Laboratory of Tumor Immunology, Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy & Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, D-13353, Berlin, Germany
<b>Languages</b>	Italian (Native Speaker), English (Proficient User), German (Goethe-Zertifikat A2)

### EDUCATION AND TRAINING

<b>Dates</b>	2005
<b>Type of qualification</b>	Scientific High School Leaving Qualification. Vote: 100/100.
<b>Name and address of employer</b>	"Benedetto Croce" High School, Rome, Italy.
<b>Dates</b>	2005
<b>Type of qualification</b>	Admission at 1st Medicine and Surgery Faculty
<b>Name and address of employer</b>	"Sapienza" University of Rome, Italy
<b>Dates</b>	2008-2011
<b>Type of qualification</b>	Medical Student at UP Cell Therapy and Cancer Immunology (Head Prof. Marianna Nuti)
<b>Name and address of employer</b>	Department of Experimental Medicine, "Sapienza" University of Rome, Italy
<b>Dates</b>	2008-2011

<b>Type of qualification</b>	Medical Student at Gynecologic Oncology Division (Director Prof. Pierluigi Benedetti Panici)
<b>Name and address of employer</b>	Department of Gynecology, Obstetrics and Urology (Head Prof. Vincenzo Gentile), "Sapienza" University of Rome, Italy
<b>Dates</b>	2008-2011
<b>Type of qualification</b>	Winner of Public University Competition, a three-year educational project for deserving students, entitled "Excellence Course". Project title: "Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial." Mentor: Prof. Marianna Nuti.
<b>Name and address of employer</b>	Department of Experimental Medicine, "Sapienza" University of Rome, Italy
<b>Dates</b>	2010
<b>Type of qualification</b>	1st Winner of Public University Competition for "Foreign Thesis Research Project Scholarships"
<b>Name and address of employer</b>	"Sapienza" University of Rome, Italy
<b>Dates</b>	27 <sup>th</sup> July 2011
<b>Type of qualification</b>	Medical degree. Vote: 110/110 <i>magna cum laude</i> . Thesis Title: "Dendritic Cells-based Immunotherapy for Gynecological Malignancies: Generation and Characterization of the Chimeric Recombinant Protein HER2-Fc". Thesis Relator: Prof. Pierluigi Benedetti Panici; Thesis Co-relator: Prof. Marianna Nuti.
<b>Name and address of employer</b>	Medicine and Surgery Faculty, "Sapienza" University of Rome.
<b>Dates</b>	5 <sup>th</sup> July 2012- 5 <sup>th</sup> July 2017
<b>Type of qualification</b>	Resident physician in Gynecology and Obstetrics
<b>Name and address of employer</b>	"Sapienza" University of Rome, Italy (Head of the Residency, Prof. Pierluigi Benedetti Panici)
<b>Dates</b>	2012-ongoing
<b>Type of qualification</b>	Medical Doctor Team member at UP Cell Therapy and Cancer Immunology (Head Prof. Marianna Nuti)
<b>Name and address of employer</b>	Department of Experimental Medicine, "Sapienza" University of Rome, Italy
<b>Dates</b>	3 <sup>rd</sup> March 2016
<b>Type of qualification</b>	"Good Scientific Practice" (GSP) Certificate
<b>Name and address of employer</b>	<i>Charité</i> Universitätsmedizin of Berlin, Germany
<b>Dates</b>	31 <sup>th</sup> March 2016
<b>Type of qualification</b>	Coursera Course Certificate: "Understanding Clinical Research: Behind the Statistics"
<b>Name and address of employer</b>	University of Cape Town: Rondebosch, South Africa
<b>Dates</b>	19 <sup>th</sup> July 2017
<b>Type of qualification</b>	Specialization in Gynecology and Obstetrics. Vote: 70/70 <i>magna cum laude</i> . Thesis title: "Clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium". Thesis Relator: Prof. Pierluigi Benedetti Panici;
<b>Name and address of employer</b>	Department of Gynecology, Obstetrics and Urology, "Sapienza" University of Rome, Italy.
<b>Dates</b>	1 <sup>st</sup> November 2016-ongoing
<b>Type of qualification</b>	Joint PhD fellow in <i>Immunological, Hematological and Rheumatological Sciences</i> (XXXII cycle, 2 <sup>nd</sup> year ongoing),
<b>Name and address of employer</b>	At "Sapienza" University of Rome, Italy, (Italian Supervisor Prof. Marianna Nuti, <i>Cell Therapy Unit and Laboratory of Tumor Immunology</i> , Department of Experimental Medicine) and <i>Charité</i> Universitätsmedizin Berlin, Germany (German Supervisor Prof. Elena Ioana Braicu, <i>Department of Gynecology, European Competence Center for Ovarian Cancer</i> , Campus Virchow Klinikum)
<b>FOREIGN EXPERIENCES</b>	
<b>Dates</b>	2011
<b>Role and Position</b>	P.I. of the research project entitled "BRCA1 Methylation Status in high-grade serous ovarian cancer patients".

<b>Institution</b>	Tumour Bank Ovarian Cancer Laboratory (TOC-Lab, <a href="http://www.toc-network.de/">http://www.toc-network.de/</a> ), Department of Gynecology, Campus Virchow Klinikum, Charité Universitätsmedizin of Berlin, Germany (Head. Prof. Dr. Jalid Sehouli)
<b>Dates</b>	2011
<b>Role and Position</b>	P.I. of the research project entitled "BRCA1 Methylation Status in high-grade serous ovarian cancer patients".
<b>Institution</b>	Epiontis GmbH, Epigenetic on tissue laboratory, Berlin, Germany.
<b>Dates</b>	August 2011
<b>Role and Position</b>	Selected as one of the 60 participants all over the world for "Novartis Biotechnology Leadership International BioCamp 2011"
<b>Institution</b>	Novartis Headquarters, Basel, Switzerland
<b>Dates</b>	Jan-Jul 2016
<b>Role and Position</b>	Clinical and Research fellow. Responsible of the following 3 research studies: 2 studies of the OCTIPS Consortium (OCTIPS - <i>Ovarian Cancer Therapy Innovative models Prolong Survival</i> - is a 7th Framework Program Research Project, funded by the European Commission and started in 2012, with Grant Agreement N° 279113-2) and 1 study of the TOC Network: 1) „Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.“ 2) „Changes occurring in intratumoral vasculature during the progression from primary to recurrent high-grade serous ovarian cancer (HGSOC): pathological and clinical implications. A study of the OCTIPS Consortium.“ 3) “Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): results of a propensity score matched (PSM) analysis of the international prospective tumor bank of ovarian cancer (TOC Network).”
<b>Institution</b>	Department of Gynecology, Campus Virchow Klinikum, Charité Universitätsmedizin of Berlin, Germany (Head. Prof. Dr. Jalid Sehouli) and Tumour Bank Ovarian Cancer Laboratory (TOC-Lab).

## TEACHING POSITIONS

<b>Dates</b>	A.Y. 2016/2017 and 2017/2018
<b>Course type</b>	II Level Master in "Immuno-Oncology" (Chair: Prof. Paolo Marchetti)
<b>Institution</b>	"Sapienza" University of Rome, Italy
<b>Dates</b>	A.Y. 2017/2018
<b>Course type</b>	NURSING PROCESS AND THERAPEUTIC CARE IN MATERNAL AND PEDIATRIC AREA - NURSING IN THE OBSTETRICS AND GYNECOLOGY AREA
<b>Institution</b>	Bechelor's Degree in Nursing Science - Sant'Andrea Hospital, "Sapienza" University of Rome, Italy

## SCIENTIFIC SOCIETIES MEMBERSHIPS

<b>Dates</b>	2009-ongoing
<b>Society</b>	MITO Group (Multicenter Italian Trials in Ovarian cancer and Gynecologic Malignancies)
<b>Dates</b>	2011-ongoing
<b>Society</b>	ESGO Group (European Society of Gynaecologic Oncology) and ENYGO Group (European Network of Young Gynae-Oncologists)
<b>Dates</b>	2012-ongoing
<b>Society</b>	EUTROC Group (European Network for Translational Research in Ovarian Cancer)
<b>Dates</b>	2014-ongoing
<b>Society</b>	SIEOG (Società Italiana di Ecografia Ostetrica e Ginecologica e Metodologie Biofisiche)

<b>Dates</b>	2015-ongoing
<b>Society</b>	ASCO member (American Society of Clinical Oncology)
<b>Dates</b>	2017-ongoing
<b>Society</b>	TOC (Tumor bank Ovarian Cancer) Network
<b>Dates</b>	2017-ongoing
<b>Society</b>	ISUOG (International Society of Ultrasound in Obstetrics and Gynecology)
<b>Dates</b>	2017 – ongoing
<b>Society</b>	SIMeP (Società Italiana di Medicina Personalizzata)

### EDITORIAL ACTIVITIES FOR INTERNATIONAL INDEXED SCIENTIFIC JOURNALS

<b>Dates</b>	2016
<b>Journal</b>	Analytical Cellular Pathology (I.F. 2015: 0.46)
<b>Role</b>	Invited Editor
<b>Dates</b>	2017
<b>Journal</b>	BioMed Research International (I.F. 2016: 2.48)
<b>Role</b>	Lead Guest Editor of the Special Issue entitled "Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets" (published in March 2018)

### REFeree FOR INTERNATIONAL INDEXED SCIENTIFIC JOURNALS

<b>Journal</b>	Tumor Biology (I.F. 2016: 3.65)
<b>Date</b>	2016 – ongoing
<b>Journal</b>	Future Oncology (I.F. 2016: 2.13)
<b>Date</b>	2017 - ongoing

### RESEARCH GRANTS

<b>Dates</b>	2009
<b>Project Title</b>	Effect of cytoreduction and chemotherapy treatment on the immunologic profile of patients affected by gynecologic malignancies.
<b>Research Chair</b>	Prof. Pierluigi Benedetti Panici
<b>Type of Grant</b>	"Sapienza" University Research Project
<b>Funded amount</b>	€ 11,000
<b>Dates</b>	2013
<b>Project Title</b>	Generation and characterization of novel recombinant immunogens to target DCs for cancer vaccines.
<b>Research Chair</b>	Dr. Ilaria Grazia Zizzari
<b>Type of Grant</b>	"Sapienza" University Research Project (Avvio alla Ricerca)
<b>Funded amount</b>	€ 3,000

**Dates** 2014  
**Project Title** Identification of Biological Prognostic Factors and Potential Therapeutic Targets in Endometrial Cancer.  
**Research Chair** Prof. Pierluigi Benedetti Panici  
**Type of Grant** "Sapienza" University Research Project  
**Funded amount** € 13,000

**Dates** 2015  
**Project Title** Primary Cytomegalovirus infection during pregnancy: comparing fetal damage and perinatal outcome with different viral genotypes.  
**Research Chair** Prof. Renato La Torre  
**Type of Grant** "Sapienza" University Research Project  
**Funded amount** € 8,000

**Dates** 2015  
**Project Title** Frailty and tumor immunology in ovarian cancer: defining new biological predictor markers for surgical outcome in elderly patients.  
**Research Chair** Dr. Ilary Ruscito  
**Type of Grant** "Sapienza" University Research Project (Avvio alla Ricerca)  
**Funded amount** € 1,000

**Dates** 2015  
**Project Title** Glycoantigens in ovarian cancer: dissecting novel patterns of immune recognition in cancer patients.  
**Research Chair** Prof. Marianna Nuti  
**Type of Grant** Investigator Grant 2015, AIRC (Associazione Italiana per la Ricerca sul Cancro)  
**Funded amount** € 312,000

**Dates** 2017  
**Project Title** Reverting cancer immune tolerance by cell-free DNA-based vaccination.  
**Research Chair** Dr. Ilary Ruscito  
**Type of Grant** "Sapienza" University Research Project (Avvio alla Ricerca)  
**Funded amount** € 1,250

**Dates** 2017  
**Project Title** Reverting cancer immune tolerance by cell-free DNA-based vaccination.  
**Research Chair** Dr. Ilary Ruscito  
**Type of Grant** Research Grants - Short-Term Grants 2017/ Forschungsstipendien – Kurzstipendien 2017, DAAD (Deutscher Akademischer Austausch Dienst)  
**Funded amount** € 3,500

## AWARDS

**Dates** 6<sup>th</sup> May 2017  
**Type of Award** **Best Research Study**, presented during the Poster Session of the *International Charité-Mayo Conference 2017*. Berlin, 3-6 May 2017.  
**Research Study Title** Exploring the clonal evolution of CD133/ALDH1-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the OCTIPS Consortium.

**Dates** 22<sup>th</sup> June 2017  
**Type of Award** **Best Oral Presentation**, during the *20<sup>th</sup> International Meeting of the European Society of Gynaecological Oncology (ESGO)*. Vienna, 4-7 November 2017.  
**Research Study Title** Changes in neoangiogenetic profile of paired primary and recurrent high-grade serous ovarian cancer (HGSOC): a study of the OCTIPS Consortium.

**Dates** 26<sup>th</sup> July 2017  
**Type of Award** **SIMeP** (Italian Society of Personalized Medicine) **Continuous Educational Program (CEP) Award 2017**

- 1) Bellati F, Napoletano C, **Ruscito I**, Pastore M, Pernice M, Antonilli M, Nuti M, Benedetti Panici P. **Complete Remission of Ovarian Cancer Induced Intractable Malignant Ascites with Intraperitoneal Bevacizumab. Immunological Observations and Literature Review.** *Investigational New Drugs* 2010; 28: 887-894. DOI:10.1007/s10637-009-9351-4  
IF 2016: 3.484
- 2) Bellati F, Napoletano C, **Ruscito I**, Liberati M, Benedetti Panici P, Nuti M. **Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy.** *Journal of Clinical Oncology* 2010; 28: e369-e370. DOI:10.1200/JCO.2010.28.6922  
IF 2016: 24.008
- 3) Benedetti Panici P, **Ruscito I**, Gasparri ML, Marchese C, Bellati F. **Vaginal Reconstruction with the Abbé-McIndoe Technique: from Dermal Grafts to Autologous in vitro Cultured Vaginal Tissue Transplant.** *Seminars in Reproductive Medicine* 2011; 29:45-54. DOI: 10.1055/s-0030-1268703  
IF 2016: 2.644
- 4) Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, Zizzari IG, **Ruscito I**, Rahimi H, Benedetti Panici P, Rughetti A. **Immune effects of Trastuzumab.** *Journal of Cancer* 2011; 2: 317-323. DOI:10.7150/jca.2.317  
IF 2016: 2.916
- 5) Bellati F, Napoletano C, Gasparri ML, **Ruscito I**, Marchetti C, Pignata S, Tomao F, Benedetti Panici P, Nuti M. **Current Knowledge and Open Issues regarding Bevacizumab in Gynaecological Neoplasms.** *CriticalReviewsinOncology/Hematology*.2012;83(1):35-46.DOI: 10.1016/j.critrevonc.2011.09.006  
IF 2016: 4.971
- 6) Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, **Ruscito I**, Caccetta J, Rughetti A, Benedetti-Panici P, Nuti M. **Monoclonal antibodies in gynecological cancer: a critical point of view.** *Clin Dev Immunol*. 2011; 2011:890758. DOI:10.1155/2011/890758  
IF 2015: 3.603
- 7) Bellati F, Napoletano C, Ruscito I, Visconti V, Antonilli M, Gasparri ML, Zizzari IG, Rahimi H, Palaia I, Rughetti A, Benedetti Panici P, Nuti M. **Past, present and future strategies of immunotherapy in gynecological malignancies.** *Curr Mol Med*. 2013;13(4):648-69. DOI: 10.2174/1566524011313040014  
IF 2016: 2.345
- 8) Bellati F, Gasparri ML, Ruscito I, Caccetta J, Benedetti Panici P. **Minimal Invasive Approaches for Large Ovarian Cysts: a Careful Choice.** *Arch Gynecol Obstet*. 2013;287(3):615-6. DOI: 10.1007/s00404-012-2560-7.  
IF 2016: 2.090
- 9) Leone Roberti Maggiore U, Bellati F, **Ruscito I**, Gasparri ML, Alessandri F, Venturini PL, Ferrero S. **Monoclonal antibodies therapies for ovarian cancer.** *Expert Opin Biol Ther*. 2013;13(5):739-64. DOI: 10.1517/14712598.2013.767328.  
IF 2016: 3.684
- 10) Bellati F, **Ruscito I\***, Gasparri ML, Antonilli M, Pernice M, Vallone C, Morano G, Chirletti P, Berloco PB, Panici PB. **Effects of unilateral ovariectomy on female fertility outcome.** *Arch Gynecol Obstet*. 2014;290(2):349-53. DOI: 10.1007/s00404-014-3194-8.  
\* Corresponding Author  
IF 2016: 2.090
- 11) Panici PB, Marchetti C, Salerno L, Musella A, Vertechy L, Palaia I, Perniola G, **Ruscito I**, Boni T, Angioli R, Muzii L. **Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.** *Ann Surg Oncol*. 2014;21(9):3036-41. DOI: 10.1245/s10434-014-3714-6.  
IF 2016: 4.041
- 12) **Ruscito I**, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI. **BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).** *Eur J Cancer*. 2014 Aug;50(12):2090-8. DOI: 10.1016/j.ejca.2014.05.001.  
IF 2016: 6.029
- 13) Marchetti C, Gasparri ML, **Ruscito I**, Palaia I, Perniola G, Carrone A, Farooqi AA, Pecorini F, Muzii L, Panici PB **Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)** *Crit Rev Oncol Hematol*. 2015;94(3):302-10. DOI: 10.1016/j.critrevonc.2015.02.001.  
IF 2016: 4.971

- 14) Benedetti Panici P, Palaia I, Marchetti C, **Ruscito I**, Fischetti M, Musella A, Di Donato V, Perniola G, Vertechy L, Muzii L. **Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study**. *Oncology*. 2015;89(2):103-10. doi: 10.1159/000381461.  
IF 2016: 2.262
- 15) Salerno L, Marchetti C, Bevilacqua E, Musella A, Riganelli L, **Ruscito I**, Perniola G, Muzii L, Benedetti Panici P. **Beyond the beyond: first case of nine cytoreductive surgeries in a long-surviving platinum-resistant ovarian cancer patient. Case report**. *Tumori* 2016;102(Suppl. 2). DOI: 10.5301/tj.5000427.  
IF 2016: 1.233
- 16) Gasparri ML, Savone D, Besharat RA, Farooqi AA, Bellati F, **Ruscito I**, Panici PB, Papadia A. **Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer**. *Tumor Biol* 2016;37(1):71-5. DOI 10.1007/s13277-015-4299-9  
IF 2016: 3.650
- 17) Musella A, Marchetti C, Gasparri ML, Salerno L, Casorelli A, Domenici L, Imperiale L, **Ruscito I**, Abdal Halim T, Palaia I, Di Donato V, Pecorini F, Monti M, Muzii L, Panici PB. **PARP inhibition: A promising therapeutic target in ovarian cancer**. *Cell Mol Biol (Noisy-le-grand)* 2015;61(6):44-61.  
IF 2016: 0.920
- 18) **Ruscito I**, Gasparri ML, Marchetti C, De Medici C, Bracchi C, Palaia I, Imboden S, Mueller MD, Papadia A, Muzii L, Panici PB. **Cediranib in ovarian cancer: state of the art and future perspectives**. *Tumor Biol* 2016;37(3):2833-9.  
IF 2016: 3.650
- 19) Antonilli M, Rahimi H, Visconti V, Napoletano C, **Ruscito I**, Zizzari IG, Caponnetto S, Barchiesi G, Iadarola R, Pierelli L, Rughetti A, Bellati F, Panici PB, Nuti M. **Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial**. *Int J Oncol* 2016;48(4):1369-78.  
IF 2016: 3.079
- 20) Dimitrova D\*, **Ruscito I\***, Olek S, Richter R, Hellweg A, Türbachova I, Wopen H, Baron U, Braicu EI, Sehouli J. **Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium**. *Tumor Biol* 2016;37(9):12329-12337.  
\* Equally contributed.  
IF 2016: 3.650
- 21) **Ruscito I**, Gasparri ML, Braicu EI, Bellati F, Raio L, Sehouli J, Mueller M, Benedetti Panici P, Papadia A. **Sentinel node mapping in cervical and endometrial cancer. Indocyanine green versus other conventional dyes: a meta-analysis**. *Ann Surg Oncol*. 2016;23(11):3749-56.  
IF 2016: 4.041
- 22) Di Donato V, Schiavi MC, **Ruscito I**, Visentin VS, Palaia I, Marchetti C, Fischetti M, Monti M, Muzii L, Benedetti Panici P. **Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer**. *Ann Surg Oncol*. 2016;23:841-849.  
IF 2016: 4.041
- 23) Napoletano C, Bellati F, **Ruscito I**, Pernice M, Zizzari IG, Caponnetto S, Tomao F, Frigerio L, Liberati M, Rughetti A, Caserta D, Benedetti Panici P, Nuti M. **Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells**. *Anticancer Research* 2016; 36: 5109-5116.  
IF 2016: 1.937
- 24) Gasparri ML, **Ruscito I\***, Bolla D, Benedetti Panici P, Mueller MD, Papadia A. **The efficacy of fibrin sealant patches in reducing the incidence of lymphatic morbidity after radical lymphadenectomy: a Meta-analysis**. *Int J Gynecol Cancer* 2017; 27(6):1283-1292.  
\* Corresponding Author  
IF 2016: 2.369
- 25) Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, **Ruscito I**, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Benedetti Panici P. **Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer**. *Tumor Biol* 2017 May;39(5):1010428317695525.  
IF 2016: 3.650
- 26) **Ruscito I\***, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI. **Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1**

**(ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium** Eur J Cancer 2017; 79: 214-225.

\* Corresponding Author

IF 2016: 6.029

27) Sun T\*, **Ruscito I\***, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Benedetti Panici P, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI. **Genetic versus epigenetic BRCA1 silencing pathways: clinical effects in primary ovarian cancer patients. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium**. Int J Gynecol Cancer 2017;27:1658-1665.

\* Equally contributed

IF 2016: 2.369

28) Gasparri ML, Bardhi E, **Ruscito I\***, Papadia A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD, Benedetti Panici P. **PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track?** Geburtshilfe Frauenheilkd. 2017; 77(10):1095-1103.

\* Corresponding Author

IF 2016: 1.175

29) Battisti F, Napoletano C, Rahimi Koshkaki H, Belleudi F, Zizzari IG, **Ruscito I**, Palchetti S, Bellati F, Benedetti Panici P, Torrisi MR, Caracciolo G, Altieri F, Nuti M, Rughetti A. **Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells**. Front Immunol. 2017;8:1179.

IF 2016: 6.429

30) Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, **Ruscito I**, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S. **Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer**. Neoplasia. 2018;20(3):280-288.

IF 2016: 5.006

31) **Ruscito I\***, Braicu EI, Gasparri ML, Zizzari IG. **Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets**. BioMed Research International 2018 Mar 1;2018:6532019. doi: 10.1155/2018/6532019.

\* Corresponding Author

IF 2016: 2.476

32) Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, **Ruscito I**, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M. **TK Inhibitor Pazopanib Primes DCs by Downregulation of the  $\beta$ -Catenin Pathway**. Cancer Immunol Res. 2018 Jun;6(6):711-722.

IF 2016: 8.284

33) **Ruscito I\***, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI. **The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis**. Gynecol Oncol. 2018 Jul;150(1):151-157. doi: 10.1016/j.ygyno.2018.05.006.

\* Corresponding Author

IF 2016: 4.959

34) **Ruscito I\***, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI. **Characterisation of tumor microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact. An OCTIPS Consortium study**. British Journal of Cancer 2018 (In Press).

\* Corresponding Author

IF 2016: 6.176

**TOTAL Impact Factor (2016)**  
**TOTAL H-Index (Scopus)**  
updated June 2018  
**First Authorships**  
**Corresponding Authorships**

**144.261**  
**11**  
**9**  
**7**



## OTHER PAPERS

1) **Ruscito I.** and Banerjee S. *Homologous recombination deficiency in ovarian cancer and beyond*. Cancer Breaking News 2016, 4: 17-22.

## BOOK CHAPTERS

1) The immunobiology of cancer: from tumor escape to cancer immunoediting towards immunotherapy in gynecologic oncology.

In: Farooqi AA and Ismail M. (2017). *Molecular Oncology: Underlying Mechanisms and Translational Advancements*. ed. Springer International Publishing. ISBN: 978-3-319-53082-6; DOI: 10.1007/978-3-319-53082-6.

2) Current knowledge of miRNAs as biomarkers in Breast Cancer.

In: Farooqi AA. *Recent Trends in Cancer Biology: Spotlight on Signaling Cascades and microRNAs*. ed. Springer International Publishing. ISBN 978-3-319-71552-0; DOI: 10.1007/978-3-319-71553-7.

## SPEAKER AT NATIONAL OR INTERNATIONAL MEETINGS

1) **Ruscito I**, Braicu EI, Benedetti Panici P, Chekerov R, Dimitrova D, Ganapathi RN, Vasconcelos I, Bellati F, Fotopoulou C, Lichtenegger W, Olek S, Sehouli J. *Identificazione dello stato di metilazione del gene brca1 in pazienti affette da carcinoma dell'ovaio sieroso ad alto grado di malignità*.

La donna il fascino della ginecologia moderna tra salute e sicurezza della donna: aggiornamenti e necessità.

3° Congresso Nazionale FIOG, 2° Congresso Nazionale AGIF, Congresso Straordinario AGUI, 17° Congresso Nazionale AGICO, 14° Congresso Nazionale AGEO.  
Montecatini Terme, Italy, 12-14 April 2012.

2) **Ruscito I**. *Changes in neoangiogenetic profile of paired primary and recurrent high-grade serous ovarian cancer (HGSOC): a study of the OCTIPS Consortium*.

20<sup>th</sup> International Meeting of the European Society of Gynaecological Oncology (ESGO).  
Vienna, Austria, 4-7 November 2017.

3) **Ruscito I**. *Evolution in tumor vasculature from primary to recurrent high-grade serous ovarian cancer (hgosc): results from the "Ovarian Cancer Therapy – Innovative Models Prolong Survival" (OCTIPS) Consortium*.

Annual Meeting AGUI (Associazione Ginecologi Universitari Italiani): Mamma Donna Feto  
Milano, Italy, 30 November – 1 December 2017

## MOST RELEVANT ABSTRACTS PRESENTED AT INTERNATIONAL MEETINGS

1) Bellati F, Gasparri ML, Pernice M, Musella A, Donfrancesco C, **Ruscito I**, Visconti V, Benedetti Panici P. Improvement of QoL after hormone replacement therapy in cervical cancer survivors.

14th World Congress of Gynecological Endocrinology  
Florence, Italy, 4-7th March 2010

2) Benedetti Panici P, Napoletano C, Bellati F, Gasparri ML, **Ruscito I**, Pernice M, Pastore M, Antonilli M, Maffucci D, Nuti M. Improvement of Quality of Life and Immunological Fitness targeting VEGF in platinum refractory ovarian cancer patient.

14th World Congress of Gynecological Endocrinology  
Florence, Italy, 4-7th March 2010

3) Bellati F, Perniola G, Pernice M, Pastore M, Maffucci D, **Ruscito I**, Gasparri ML, Achilli C, Tomao F, Benedetti-Panici P. Vaginal Reconstruction With The Abbe-McIndoe Technique: From Dermal Grafts To Autologous In Vitro Cultured Vaginal Tissue Transplant.

2nd International Video Workshop (IVW) on radical surgery in gynecologic oncology.  
Prague, Czech Republic, 8-10th April 2010

- 4) Bellati F, **Ruscito I**, Gasparri ML, Marchetti C, Tomao F, Pernice M, Rossi A, Zito R, Mancini N, De Vivo A, Benedetti Panici P. Tertiary Cytoreductive Surgery Versus Third Line Chemotherapy For Recurrent Ovarian Cancer. A Prospective Study.  
13th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2010)  
Prague, Czech Republic, 23-26th October 2010
- 5) Palaia I, Donfrancesco C, **Ruscito I**, Domenici L, Faiano P, Besharat A, Caradio F, Bracchi C, Benedetti Panici P. Improvement of QoL after hormone replacement therapy in cervical cancer survivors.  
13th World Congress on Menopause  
Rome, Italy, 8-11th June 2011
- 6) **Ruscito I**, Braicu EI, Benedetti Panici P, Chekerov R, Dimitrova D, Ganapathi RN, Vasconcelos I, Bellati F, Fotopoulou C, Lichtenegger W, Olek S, Sehouli J. BRCA1 methylation status in high-grade serous ovarian cancer (HGSOC) patients (pts).  
ASCO Annual Meeting 2012  
Chicago, Illinois, 1-5 June 2012
- 7) **Ruscito I**, Braicu EI, Benedetti Panici P, Chekerov R, Dimitrova D, Ganapathi RN, Vasconcelos I, Bellati F, Fotopoulou C, Lichtenegger W, Olek S, Sehouli J. Clinical impact of brca1 gene methylation status in high-grade serous ovarian cancer (HGSOC) patients.  
14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS)  
Vancouver, Canada, October 13-16, 2012
- 8) **Ruscito I**, Caponnetto S, Zizzari IG, Pernice M, Liberati M, Frigerio L, Tomao F, Benedetti Panici P, Nuti M, Bellati F, Napoletano C. Immunological and clinical impact of Cancer Stem Cells in Squamous Vulvar Cancer patients: immunohistochemical assessment of CD133-expressing cancer cells.  
6th Annual EUTROC Meeting  
London, UK, 12th July 2014
- 9) Kalachand RD, **Ruscito I**, Dimitrova D, Benedetti Panici P, Sehouli J, Olek S, Braicu EI, Lu L, Katsaros D, Yu H, Carey MS, Broaddus R, Lu KH, Mills GB, Harrell MI, Agnew KJ, Swisher EM, Grogan W, Stordal B, Hennessy B. Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.  
ASCO Annual Meeting 2015  
Chicago, Illinois, 29th May-2nd June 2015
- 10) Gasparri ML, **Ruscito I**, La Russa C, Palaia I, Perniola G, Di Donato V, Marchetti C, Rurgo S, Crispino S, Cursio W, Muzii L, Berloco P, Benedetti Panici P. A ten-year experience of hepatic surgery during cytoreduction for primary or recurrent ovarian cancer.  
ESGO 19th Meeting 2015,  
Nice, France, 24th -27th October 2015.
- 11) **Ruscito I**, Gasparri ML, Marchetti C, Crispino S, La Russa C, Petriglia G, Di Donato V, Palaia I, Perniola G, Muzii L, Benedetti Panici P. BMI is a key prognostic factor in stage IIIC-IV ovarian cancer diagnosed prior 65 years old: a 10-year survival analysis.  
ESGO 19th Meeting 2015,  
Nice, France, 24th -27th October 2015.
- 12) **Ruscito I**, Gasparri ML, Marchetti C, Crispino S, La Russa C, Di Donato V, Palaia I, Perniola G, Musella A, Muzii L, Benedetti Panici P. A 10-year age-related survival analysis on cytoreductive surgery in stage IIIC-IV ovarian cancer: elderly vs younger women.  
2016 Cancer Survivorship Symposium: Advancing Care and Research  
San Francisco, California, 15-16th January 2016
- 13) **Ruscito I**, Sehouli J, Vergote I, Gabra H, Vandersticherle A, Cacsire-Castillo D, Benedetti Panici P, Kreuzinger C, Charlie Gourley C, Kulbe H, Darb-Esfahani S, Braicu EI. The co-expression of cancer stem cell biomarkers CD133 and ALDH1 is an independent prognostic factor for both PFS and OS in High-grade serous ovarian cancer (HGSOC) patients. A study of the OCTIPS Consortium.  
ESGO 2016 State of the Art conference: Prevention of gynecological malignancies  
Antalya, Turkey, 8-10th September 2016
- 14) Braicu EI, Woopen H., Glajzer J., Hunsicker O., Woelber L., Feldheiser A., van Nieuwenhuysen E, Mueller MD, Concin N., Achimas P, **Ruscito I.**, Mahner S., Benedetti-Panici P., Gasparri M.L., Papadia

A., Birrer M., Vergote I., Darb-Esfahani S., Sehouli J. Clinical Characterization of Long Term Survivors (LTS) in Ovarian Cancer (OC): Results of a Propensity Score Matched (PSM) Analysis of the international prospective tumor bank for ovarian cancer (TOC Network).

ASCO Annual Meeting 2017

Chicago, Illinois, 2th-6th June 2017

15) **Ruscito I**, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI . Exploring the clonal evolution of CD133/ALDH1-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the OCTIPS Consortium.

International Charité-Mayo Conference 2017

Berlin, Germany, 3-6 May 2017

I authorize the processing of personal data contained in my *curriculum vitae* by art. 13 D. Decree 196/2003

*Ilary Ruscito*

Rome, 9<sup>th</sup> May 2019